Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard L Wasserman

Showing results (61-70 of 98) with videos related to

Pageof 10
Sort By:
Journal of Agricultural and Food Chemistry|December 15, 2016
Identification and Characterization of Ana o 3 Modifications on Arginine-111 Residue in Heated Cashew NutsChristopher P Mattison, Casey C Grimm, Yichen Li, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|January 4, 2011
Prospective study of C1 esterase inhibitor in the treatment of successive acute abdominal and facial hereditary angioedema attacksRichard L Wasserman, Robyn J Levy, Againdra K Bewtra, et al.
Immunotherapy|July 29, 2016
Recombinant human hyaluronidase facilitated subcutaneous immunoglobulin treatment in pediatric patients with primary immunodeficiencies: long-term efficacy, safety and tolerabilityRichard L Wasserman, Isaac Melamed, Lisa Kobrynski, et al.
Clinical Pharmacokinetics|May 11, 2011
Pharmacokinetics of subcutaneous IgPro20 in patients with primary immunodeficiencyRichard L Wasserman, Isaac Melamed, Robert P Nelson, et al.
Frontiers in Immunology|July 26, 2021
Efficacy, Safety and Tolerability of a New 10% Intravenous Immunoglobulin for the Treatment of Primary ImmunodeficienciesElena E Perez, Jacques Hébert, Anne K Ellis, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|September 9, 2022
Information needs of patients considering oral immunotherapy for food allergyDouglas Paul Mack, Matthew Greenhawt, Paul J Turner, et al.
Journal of Clinical Immunology|August 19, 2024
Long-Term Safety of Facilitated Subcutaneous Immunoglobulin 10% Treatment in US Clinical Practice in Patients with Primary Immunodeficiency Diseases: Results from a Post-Authorization Safety StudyArye Rubinstein, Mohsen Mabudian, Donald McNeil, et al.
Journal of Clinical Immunology|June 22, 2016
Efficacy, Safety, and Pharmacokinetics of a New 10 % Liquid Intravenous Immunoglobulin Containing High Titer Neutralizing Antibody to RSV and Other Respiratory Viruses in Subjects with Primary Immunodeficiency DiseaseRichard L Wasserman, William Lumry, James Harris, et al.
Journal of Clinical Immunology|July 17, 2010
Prospective study of rapid relief provided by C1 esterase inhibitor in emergency treatment of acute laryngeal attacks in hereditary angioedemaTimothy J Craig, Richard L Wasserman, Robyn J Levy, et al.
Immunotherapy|September 21, 2022
Systemic IgG exposure and safety in patients with primary immunodeficiency: a randomized crossover study comparing a novel investigational wearable infusor versus the Crono pumpRichard L Wasserman, Charlotte Cunningham-Rundles, John Anderson, et al.
Pageof 10

Showing results (61-70 of 98) with videos related to

Sort By:
Pageof 10
Journal of Agricultural and Food Chemistry|December 15, 2016
Identification and Characterization of Ana o 3 Modifications on Arginine-111 Residue in Heated Cashew NutsChristopher P Mattison, Casey C Grimm, Yichen Li, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|January 4, 2011
Prospective study of C1 esterase inhibitor in the treatment of successive acute abdominal and facial hereditary angioedema attacksRichard L Wasserman, Robyn J Levy, Againdra K Bewtra, et al.
Immunotherapy|July 29, 2016
Recombinant human hyaluronidase facilitated subcutaneous immunoglobulin treatment in pediatric patients with primary immunodeficiencies: long-term efficacy, safety and tolerabilityRichard L Wasserman, Isaac Melamed, Lisa Kobrynski, et al.
Clinical Pharmacokinetics|May 11, 2011
Pharmacokinetics of subcutaneous IgPro20 in patients with primary immunodeficiencyRichard L Wasserman, Isaac Melamed, Robert P Nelson, et al.
Frontiers in Immunology|July 26, 2021
Efficacy, Safety and Tolerability of a New 10% Intravenous Immunoglobulin for the Treatment of Primary ImmunodeficienciesElena E Perez, Jacques Hébert, Anne K Ellis, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|September 9, 2022
Information needs of patients considering oral immunotherapy for food allergyDouglas Paul Mack, Matthew Greenhawt, Paul J Turner, et al.
Journal of Clinical Immunology|August 19, 2024
Long-Term Safety of Facilitated Subcutaneous Immunoglobulin 10% Treatment in US Clinical Practice in Patients with Primary Immunodeficiency Diseases: Results from a Post-Authorization Safety StudyArye Rubinstein, Mohsen Mabudian, Donald McNeil, et al.
Journal of Clinical Immunology|June 22, 2016
Efficacy, Safety, and Pharmacokinetics of a New 10 % Liquid Intravenous Immunoglobulin Containing High Titer Neutralizing Antibody to RSV and Other Respiratory Viruses in Subjects with Primary Immunodeficiency DiseaseRichard L Wasserman, William Lumry, James Harris, et al.
Journal of Clinical Immunology|July 17, 2010
Prospective study of rapid relief provided by C1 esterase inhibitor in emergency treatment of acute laryngeal attacks in hereditary angioedemaTimothy J Craig, Richard L Wasserman, Robyn J Levy, et al.
Immunotherapy|September 21, 2022
Systemic IgG exposure and safety in patients with primary immunodeficiency: a randomized crossover study comparing a novel investigational wearable infusor versus the Crono pumpRichard L Wasserman, Charlotte Cunningham-Rundles, John Anderson, et al.
Pageof 10